FDA limits public advisory committee meetings. This is despite efforts by the public and other stakeholders for greater transparency. FDA decisions are increasingly controversial. The agency avoids public advisory meetings. These committees serve to discuss important decisions. Limiting meetings reduces public scrutiny of the process. Stakeholders demand a more open practice. However, the FDA continues to take this approach.